NDAORALTABLET
Approved
Jul 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
TRIBENZOR (olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide) by Pfizer is regulation. Approved for hypertension, to lower blood pressure. First approved in 2010.
Drug data last refreshed 23m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIBENZOR is a fixed-dose triple combination tablet containing olmesartan medoxomil (ARB), amlodipine (calcium channel blocker), and hydrochlorothiazide (thiazide diuretic) approved for hypertension management. It works through three complementary mechanisms: blocking angiotensin II vasoconstriction, inhibiting calcium-mediated vascular smooth muscle contraction, and promoting sodium/water excretion via the kidney. This triple-action approach addresses multiple pathways of blood pressure regulation.
$0.002BPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with modest Part D utilization ($2M annually, 2,503 claims in 2023), signaling contraction headcount and transition planning within the brand team.
Mechanism of Action
regulation. Specifically, amlodipine blocks the contractile effects of calcium on cardiac and vascular smooth muscle cells; olmesartan medoxomil blocks the vasoconstriction and sodium retaining effects of angiotensin II on cardiac, vascular smooth muscle, adrenal and renal cells; and…
Worked on TRIBENZOR at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.